Baiyunshan Pharma renews GPHL connected transactions for 2026

Guangzhou Baiyunshan Pharmaceutical Holdings Co., Ltd. has entered into a new continuing connected transactions agreement with its controlling shareholder, Guangzhou Pharmaceutical Holdings Limited (GPHL), effective from January 1, 2026, to December 31, 2026. This renewal follows the impending expiry of existing agreements on December 31, 2025, and aims to continue business with GPHL and its subsidiaries.

The new agreement covers various transactions, including purchases and sales of pharmaceuticals and materials, provision and receipt of labor services, entrusted processing, trademark license grants, and asset leasing. The aggregate annual cap for these transactions for the year ending December 31, 2026, is set at RMB39,550.00. This cap was determined based on GPHL's and the company's recent operating conditions, expected business growth, and historical transaction volumes.

Given that GPHL holds approximately 45.04% of the company's issued share capital, these transactions constitute continuing connected transactions under Hong Kong Listing Rules. As one or more applicable percentage ratios exceed 0.1% but are less than 5%, the new agreement is subject to reporting, announcement, and annual review requirements but is exempt from independent shareholders' approval.